Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock

Arcutis Biotherapeutics reported past conference data on its ZORYVE portfolio, including Phase 2 INTEGUMENT-INFANT results in atopic dermatitis and multiple analyses across creams and foams for plaque psoriasis and seborrheic dermatitis, covering different strengths, formulations, and approved age ranges. The breadth of ZORYVE data across age groups, formulations, and special sites illustrates the extent to which Arcutis Biotherapeutics relies on a single franchise to support future...